StockNews.com assumed coverage on shares of Brainstorm Cell Therapeutics (NASDAQ:BCLI – Free Report) in a research report report published on Tuesday morning. The firm issued a hold rating on the biotechnology company’s stock.
Separately, Maxim Group raised Brainstorm Cell Therapeutics from a hold rating to a buy rating and set a $2.00 price target for the company in a report on Thursday, July 11th.
Check Out Our Latest Research Report on Brainstorm Cell Therapeutics
Brainstorm Cell Therapeutics Price Performance
Brainstorm Cell Therapeutics (NASDAQ:BCLI – Get Free Report) last posted its earnings results on Tuesday, May 14th. The biotechnology company reported ($0.05) earnings per share for the quarter, beating the consensus estimate of ($0.07) by $0.02. Research analysts expect that Brainstorm Cell Therapeutics will post -0.14 earnings per share for the current year.
Institutional Trading of Brainstorm Cell Therapeutics
A hedge fund recently bought a new stake in Brainstorm Cell Therapeutics stock. Kingswood Wealth Advisors LLC purchased a new position in Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI – Free Report) during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 81,050 shares of the biotechnology company’s stock, valued at approximately $46,000. Kingswood Wealth Advisors LLC owned about 0.12% of Brainstorm Cell Therapeutics at the end of the most recent reporting period. 14.33% of the stock is currently owned by institutional investors.
About Brainstorm Cell Therapeutics
Brainstorm Cell Therapeutics Inc, a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function.
Featured Stories
- Five stocks we like better than Brainstorm Cell Therapeutics
- 3 Stocks to Protect Your Portfolio from the Coronavirus Contagion
- MarketBeat Week in Review – 8/5 – 8/9
- What is the S&P/TSX Index?
- Cassava Sciences: A Hot Stock to Trade, Invest, or Avoid?
- What Are Dividend Challengers?
- The Cannabis Sector: Profitability Takes Center Stage
Receive News & Ratings for Brainstorm Cell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Brainstorm Cell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.